Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
53 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
000889-I
VRC 615: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB-0115-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
Participants currently recruited/enrolled
18-60 Years
NIAID
Monoclonal
000609-I
Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
Participants currently recruited/enrolled
4-65 Years
NIAID
Monoclonal
000536-I
VRC 614: A Phase 1, Dose Escalation, Open-Label Clinical Trial with Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0114-00-AB (L9LS), in Healthy M
No longer recruiting/follow-up only
18-50 Years
NIAID
Monoclonal
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
000193-C
Phase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell Lymphomas
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Monoclonal
22-I-0008
A Single Arm Open Label Phase 2 Trial of Anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 Infection
Recruitment has not started
18-125 Years
NIAID
Monoclonal
21-I-0003
A Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy, of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects with SCID
Participants currently recruited/enrolled
3-125 Years
NIAID
Monoclonal
21-C-0024
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
21-C-0014
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
20-I-0096
VRC 611: A Phase 1 Safety and Pharmacokinetic Study to Evaluate a Human Monoclonal Antibody (mAb) VRC-HIVMAB0102-00-AB (CAP256V2LS) Administered via Subcutaneous and Intravenous Injection in Healthy Adults
No longer recruiting/follow-up only
18-60 Years
NIAID
Monoclonal
20-I-0088
An Open-label Efficacy and Safety Study of Pozelimab in Patients with CD55 deficient Protein-losing Enteropathy (CHAPLE Disease)
Participants currently recruited/enrolled
3-125 Years
NIAID
Monoclonal
20-C-0162
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
20-C-0011
Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Completed Study; data analyses ongoing
18-125 Years
NCI
Monoclonal
19-I-0027
A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects with Indolent Systemic Mastocytosis
Participants currently recruited/enrolled
18-75 Years
NIAID
Monoclonal
19-H-0139
Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.
Participants currently recruited/enrolled
18-125 Years
NHLBI
Significance
19-C-0127
A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults with Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal
19-C-0116
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
19-C-0076
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Monoclonal
19-C-0042
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Monoclonal
19-C-0030
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
18-I-0105
VRC 609: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously with or without Recombinant Human Hyaluronidase PH20 (rHuPH2
Completed Study; data analyses ongoing
18-50 Years
NIAID
Monoclonal
18-I-0030
VRC 603: A Phase 1 Dose-Escalation Study of the Safety of AAV8-VRC07 (VRC-HIVAAV070-00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral-Treated, HIV-1 Infected Adults with Controlled Viremia
No longer recruiting/follow-up only
18-65 Years
NIAID
Monoclonal
18-I-0022
Use of Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients with Leukocyte Adhesion Deficiency Type 1 (LAD1) who have Inflammatory Pathology
Participants currently recruited/enrolled
12-65 Years
NIAID
Monoclonal
18-C-0147
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
17-I-0122
NIAID Centralized Sequencing Protocol
Participants currently recruited/enrolled
0-125 Years
NIAID
Uncertain
17-C-0164
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal
17-C-0149
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal
17-C-0127
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
17-C-0125
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Participants currently recruited/enrolled
12-125 Years
NCI
Monoclonal
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Monoclonal
17-C-0049
A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma
Completed Study; data analyses ongoing
2-125 Years
NCI
Monoclonal
17-C-0048
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
Completed Study; data analyses ongoing
18-73 Years
NCI
Monoclonal
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal
16-C-0062
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Completed Study; data analyses ongoing
18-125 Years
NCI
Monoclonal
14-I-0081
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects with Hypereosinophilic Syndrome (HES)
No longer recruiting/follow-up only
18-75 Years
NIAID
Monoclonal
14-HG-0048
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)
Participants currently recruited/enrolled
21-125 Years
NHGRI
Significance
10-H-0141
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
No longer recruiting/follow-up only
18-99 Years
NHLBI
Monoclonal
10-C-0025
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
10-C-0011
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Monoclonal
09-I-0013
Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults
Enrolling by Invitation
18-100 Years
NIAID
Significance
09-C-0025
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal
09-C-0005
Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Monoclonal
08-H-0105
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Monoclonal
06-H-0190
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)
Completed Study; data analyses ongoing
18-85 Years
NHLBI
Monoclonal
06-C-0150
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal
05-H-0242
A Pilot Study of Alemtuzumab (Campath) in Patients with Relapsed or Refractory Severe Aplastic Anemia
Completed Study; data analyses ongoing
2-110 Years
NHLBI
Monoclonal
04-DK-0021
Urinary Vitamin C Loss in Subjects with and without Diabetes
Participants currently recruited/enrolled
18-65 Years
NIDDK
Uncertain
02-I-0277
Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells
Participants currently recruited/enrolled
0-80 Years
NIAID
Monoclonal
02-H-0250
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Monoclonal
02-CC-0266
Acute Cardiac Allograft Cellular Rejection and Cardiac Allograft Vasculopathy: Identification of Diagnostic Biomarkers and Target Pathways for Preventive Therapy
Completed Study; data analyses ongoing
18-125 Years
CC
Significance
01-C-0030
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Monoclonal